GLP-1 Drugs Examined in Psychiatric Outcomes - Top-Institutions - MDSpire

GLP-1 Drugs Examined in Psychiatric Outcomes

Researchers evaluate mental health trajectories with antidiabetic therapies in patients with depression or anxiety.

  • By

  • Kathryn Wighton

  • March 26, 2026

  • 3 min

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    University of Eastern Finland
    University of Eastern Finland

    Kuopio, Finland

    Key Differentiators

    • Psychiatry
    • Endocrinology
    • Pharmacoepidemiology

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Psychiatry
    • Endocrinology
    • Clinical Research

  • #3

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Psychiatry
    • Endocrinology
    • Neuroscience

  • #4

    Karolinska Institutet
    Karolinska Institutet

    Stockholm, Sweden

    Key Differentiators

    • Psychiatry
    • Endocrinology
    • Epidemiology

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Psychiatry
    • Endocrinology
    • Clinical Pharmacology

Original Source(s)

GLP-1 Drugs Examined in Psychiatric Outcomes

  • by Kathryn Wighton

  • March 26, 2026

Related Content

Can Digital Tools Fix Bias in Mental Health Triage?

Aggression and emotional distress in adolescents: a cross-sectional chain mediation model of internet addiction and somatization

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.